Ex-vivo Functional Evaluation of Circulating Tumor Cells to Predict Chemotherapeutic ResponseFriday, 7 June 2013 at 09:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com We describe GEDI microfluidic devices and their implementation to capture and analyze CTCs in multiple diseases. GEDI device performance, functional assays, and genetic assays will be detailed with a focus on pancreatic and prostate cancer as well as patients with hereditary susceptibility syndromes. |